Biotalys Partners with 21st.BIO to Scale Biocontrol Production
Event summary
- Biotalys and 21st.BIO have formed a strategic partnership to advance the production of protein-based biocontrol solutions.
- 21st.BIO’s precision fermentation technology will support the large-scale manufacturing of Biotalys’ AGROBODY agricultural biocontrol products.
- Biotalys expects to conclude its collaboration with Novonesis as part of this transition.
- EVOCA NG, Biotalys’ first commercial biofungicide, is targeting a combined market of around USD 1.2 billion in the U.S., Europe, and Brazil.
The big picture
This partnership aligns with the growing demand for sustainable agricultural solutions, as protein-based biocontrols offer an eco-friendly alternative to chemical pesticides. The collaboration with 21st.BIO strengthens Biotalys’ technical capabilities, positioning it to compete in the USD 1.2 billion biofungicide market. The shift from Novonesis to 21st.BIO reflects Biotalys’ strategic pivot toward more scalable and cost-effective production methods.
What we're watching
- Regulatory Timelines
- The pace at which EVOCA NG secures regulatory approval in the U.S. (2028-29) and E.U. (2029-30) will determine its market entry strategy.
- Production Scaling
- Whether 21st.BIO’s fermentation technology can reduce production costs and accelerate the commercialization of Biotalys’ biocontrol products.
- Funding Strategy
- How Biotalys will secure additional financing to support the development and commercialization of its AGROBODY biocontrol portfolio.
Related topics